The Latest in Aggressive Lymphomas

sNDA gets priority review for CLL/SLL

October 18, 2018

FDA issues draft guidance on MRD

October 16, 2018

Phase 1 NHL, ALL trials placed on clinical hold

October 10, 2018

Variant not associated with CLL, AIHA, or ITP in certain patients

October 8, 2018

System may better predict thrombosis in lymphoma

October 8, 2018

Weighing the costs of CAR T-cell therapy

October 7, 2018

CAR T therapy being explored in Hodgkin lymphoma

October 6, 2018

Duvelisib bests ofatumumab as monotherapy for treatment of CLL/SLL

October 5, 2018

5-year remission rates with combo prove durable in MCL

October 4, 2018

Ground-breaking therapy comes with distinct challenges

October 2, 2018

Two immunologists receive Nobel Prize in medicine

October 1, 2018

Brentuximab improves survival in older HL patients

October 1, 2018

FDA lifts partial hold on tazemetostat trials

September 26, 2018

FDA approves duvelisib for CLL/SLL and FL

September 25, 2018

Drug approved as part of frontline therapy for HL

September 25, 2018